Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

Stockholders’ Equity (Details Narrative) - USD ($)				3 Months Ended	6 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 14, 2023	Mar. 23, 2022	Aug. 20, 2021	Mar. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 27, 2023	Jun. 26, 2023	Apr. 17, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares issued					0					0
Preferred stock, shares outstanding					0					0
Authorized shares of common stock					100,000,000		100,000,000	50,000,000		100,000,000
Net proceeds from common stock					$ 6,352,077
Sales Agreement [Member]
Class of Stock [Line Items]
Number of shares issued					569,648
Shares issue price per share					$ 1.22
Gross proceeds from common stock					$ 693,000
Net proceeds from common stock					$ 672,000
Sales Agreement [Member] \| Maximum [Member]
Class of Stock [Line Items]
Maximum value to be sold at the market offering			$ 30,000,000.0
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Number of shares issued					50,000
Shares issue price per share					$ 1.08
Net proceeds from common stock					$ 54,000
Threshold price		$ 1.00
Purchase Agreement [Member] \| Maximum [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Commitment to purchase common stock		$ 15,000,000.0
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Accredited Investor [Member]
Class of Stock [Line Items]
Number of shares issued	7,812,544
Shares issue price per share	$ 0.80
Gross proceeds from common stock	$ 6,300,000
Net proceeds from common stock	$ 5,600,000
Restrictions to issue stock	The Purchase Agreement provides that, subject to certain exceptions, until the earlier of (i) 90 days after the closing of the Offering or (ii) the trading day following the date that our common stock’s closing price exceeds $2.00 for a period of 10 consecutive trading days, neither we nor our subsidiary will issue or enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents.
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Cash fee percentage	8.00%
Reimbursement fees	$ 60,000
Consulting Agreement [Member] \| Spartan Capital Securites LLC [Member]
Class of Stock [Line Items]
Warrants to purchase common stock, shares									3,160,130
Warrant exercise price									$ 1.02
Warrant term									3 years
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued				8,432,192	8,432,192